NCT01582152 - Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Brain NeoplasmsCentral Nervous System Neoplasms

Interventions

DRUG

TPI287

"Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.~Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."

DRUG

Bevacizumab

Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston